Advancing insulin delivery technique for people with diabetes

Forum for Injection Technique and Therapy Expert Recommendations (FITTER) Forward

Refreshed, evidence-based injection technique recommendations based on literature review and recent expert consensus

2025 recommendations

Introduction

Welcome to the Forum for Injection Technique and Therapy Expert Recommendations (FITTER) Forward, a global initiative which aims to improve diabetes care by educating healthcare providers, people with diabetes, and caregivers on proper insulin delivery techniques, with a focus on injection.

FITTER Forward provides an evidence-based refresh of injection technique recommendations from 2016 based on literature review and expert consensus. The recommendations are updated to reflect advancements in insulin delivery technology and best practices, while also championing widely-established and adopted key messages that remain relevant.

FITTER Forward discussions covered:

  • State-of-the-art insulin injection technology
  • Lipohypertrophy risk reduction
  • User-friendly insulin delivery for persons with diabetes and their providers
image description

Mission

embecta is a global diabetes care company that is leveraging its 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of approximately 2,000 employees around the globe. With the creation of the first insulin delivery device, we delivered an innovation that moved the management and treatment of diabetes forward.

Whether you’re newly diagnosed or transitioning to a new line of therapy, our mission is to make your everyday experience as comfortable and convenient as possible, while also working to advance a new generation of life-changing solutions.

Funding Disclosures

embecta is committed to upholding the highest ethical standards for peer-reviewed publications and to engaging with external authors in a collaborative manner. Professional medical writing services will be provided by a medical communications agency and would be sponsored by embecta to facilitate efficient and timely development of materials.